Search results for "Moi"

showing 10 items of 2109 documents

FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.

2016

The chemoimmunotherapy FCR (fludarabine and cyclophosphamide with rituximab) is the standard first-line treatment for physically fit chronic lymphocytic leukemia (CLL) patients. To assess the risks and benefits, we investigated health-related quality of life (HRQOL). 817 untreated CLL patients received either FC or FCR within the GCLLSG CLL8 trial. The European Organization for Research and Treatment of Cancer Quality of life Questionnaire C30 was sent to all patients at baseline, after 3, 6, and 12 months and then yearly as follow-up. A total of 769 (94%) of 817 patients completed at least one questionnaire. Comparing HRQOL of CLL patients with the general German population, CLL patients' …

AdultMaleCancer Researchmedicine.medical_specialtyCyclophosphamideChronic lymphocytic leukemiaMedication Adherence03 medical and health sciences0302 clinical medicineSex FactorsQuality of lifeChemoimmunotherapyhemic and lymphatic diseasesInternal medicineSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCyclophosphamideAgedAged 80 and overbusiness.industryCase-control studyHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellhumanitiesFludarabineLeukemiaTreatment OutcomeOncology030220 oncology & carcinogenesisCase-Control StudiesPhysical therapyQuality of LifeRituximabFemalebusinessRituximabVidarabine030215 immunologymedicine.drugFollow-Up StudiesLeukemialymphoma
researchProduct

Basaloid squamous cell carcinoma of the esophagus: diagnosis and prognosis.

1997

BACKGROUND. Basaloid squamous cell carcinoma (BSCC) is a recently recognized, poorly differentiated variant of squamous cell carcinoma (SCC), which is located predominantly in the upper aerodigestive tract. METHODS. In this study, clinical and pathologic parameters of 17 BSCCs and 133 typical SCCs of the esophagus that underwent potentially curative resection (no distant metastases, no residual tumor) were compared. In addition, light microscopic, electron microscopic, and immunohistochemical features of BSCC were investigated, to determine whether this type of carcinoma could be differentiated from other poorly differentiated carcinomas of the esophagus. RESULTS. Light microscopic study sh…

AdultMaleCancer Researchmedicine.medical_specialtyPathologyEsophageal NeoplasmsApoptosisEpitheliumDiagnosis DifferentialCytokeratinNecrosisSex FactorsCarcinoma BasosquamousmedicineCarcinomaHumansNeoplasm InvasivenessEsophagusBasaloid Squamous Cell CarcinomaAgedNeoplasm StagingAged 80 and overMucous Membranebusiness.industryCarcinoma in situS100 ProteinsAge FactorsCell DifferentiationMiddle Agedmedicine.diseasePrognosisAntigens DifferentiationImmunohistochemistryActinsSurvival Ratestomatognathic diseasesMicroscopy Electronmedicine.anatomical_structureOncologyEpidermoid carcinomaDysplasiaCarcinoma Squamous CellKeratinsHistopathologyFemalebusinessCarcinoma in SituCell DivisionCancer
researchProduct

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin…

1998

We carried out an open, randomized, phase III, multicenter clinical trial to compare, in neo-adjuvant setting, the clinical response and toxicity of the combination chemotherapy cisplatin + 5-FU with the same combination plus s.c. recombinant interleukin-2 (rIL-2) in patients with advanced (stage III IV) head and neck squamous-cell carcinoma (HNSCC). Regimen A was the classical Al Sarraf treatment: 100 mg/m2 cisplatin i.v. on day 1 plus 1000 mg m(-2) day(-1) 5-FU on days 1-5 as a continuous infusion. Regimen B was the same as regimen A plus 4.5 MIU/day rIL-2 s.c. on days 8-12 and 15-19. Treatment was repeated every 3 weeks for three cycles. A total of 33 patients were enrolled in the study;…

AdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmunologyAntineoplastic AgentsGastroenterologyGroup Blaw.inventionRandomized controlled triallawInternal medicinemedicineHumansImmunology and AllergyAgedChemotherapybusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryRegimenOncologyEpidermoid carcinomaHead and Neck NeoplasmsFluorouracilCarcinoma Squamous CellInterleukin-2Drug Therapy CombinationFemaleFluorouracilCisplatinbusinessProgressive diseasemedicine.drugCancer Immunology, Immunotherapy
researchProduct

Radiation response non-invasively imaged by [18F]FDG-PET predicts local tumor control and survival in advanced oral squamous cell carcinoma

2003

It is a major challenge to preoperatively identify patients who will profit from surgery of advanced oral cancer. In multimodality therapy, response to neoadjuvant radiation correlates to treatment success. Hence, for preoperative decisions, assessment of treatment response is required. Therefore, we analysed the prognostic significance of glucose metabolism after preoperative radiotherapy. [(18)F]FDG-PET investigations were performed for re-staging 35 patients after neoadjuvant radiotherapy (36Gy) immediately prior to tumor resection. Emission and transmission measurements were obtained and SUV's were calculated for the sites of maximum [(18)F]FDG-uptake. Subpopulations of "low" (SUV4) and…

AdultMaleCancer Researchmedicine.medical_treatmentStandardized uptake valuePremisesFluorodeoxyglucose F18Odds RatiomedicineHumansRadical surgerySurvival rateSurvival analysisNeoadjuvant therapyAgedAged 80 and overAnalysis of Variancebusiness.industryMiddle AgedPrognosisNeoadjuvant TherapySurvival RateRadiation therapyTreatment OutcomeOncologyEpidermoid carcinomaMultivariate AnalysisCarcinoma Squamous CellFemaleMouth NeoplasmsRadiotherapy AdjuvantRadiopharmaceuticalsOral SurgeryNuclear medicinebusinessFollow-Up StudiesTomography Emission-ComputedOral Oncology
researchProduct

Short review: Field recovery and potential information value of small elements of the skeleton

2011

The recovery of small elements of the skeleton (e.g. hyoid, carpals, and hand and foot phalanges) is one of the established tasks of the archaeologist and physical anthropologist when working in the field, whether in an archaeological or forensic context. In the present work, we illustrate the field location of ossified laryngeal cartilages, hand sesamoids, and the medial clavicular epiphyses. The potential information offered by these elements is briefly summarized. The frequency of these elements observed in a cemetery dating from 1943 indicates the possibility that these elements could be found in other contexts at a higher frequency than expected.

AdultMaleHistoryLaryngeal CartilagesContext (language use)Laryngeal cartilageSkeleton (category theory)Bone and BonesAnthropology PhysicalYoung AdultOsteogenesisHumansCemeteriesInformation valuePrisonersHistory 20th CenturyPhalanxClavicleArchaeologyField (geography)ArchaeologySpainAnthropologySesamoid BonesEpiphysesCognitive psychologyHOMO
researchProduct

Vocal function following laser and conventional surgery of small malignant vocal fold tumours

1996

AbstractIn the disecribed study, 26 patients after conventional, and 27 patients after laser cordectomy were examined six months or more after the operation. Videolarybogstroboscopy revealed that patients after laser cordectomy more often phonate on a purely glottic level (81 per cent) in comparison to patienbts after conventional cordectomy (19 per cent). Webs were more frequent and more extended after conventional cordectomy compared to endoscopic laser surgery. The maximal phonation time showed a very wide range with a mean value of 9 to 10 sec; there was no statistical difference between the groups of patients. Using yanagihara's classification of sonograms, a better voice quality was m…

AdultMaleLaser surgeryLarynxmedicine.medical_specialtySound SpectrographyVoice Qualitymedicine.medical_treatmentLaryngoscopyVocal CordsStroboscopePhonationHumansMedicinePhonationLaryngeal NeoplasmsAgedAged 80 and overLaryngoscopymedicine.diagnostic_testbusiness.industryGeneral MedicineMiddle AgedEndoscopySurgerymedicine.anatomical_structureOtorhinolaryngologyEpidermoid carcinomaCarcinoma Squamous CellCordectomyFemaleLaser TherapyRadiologybusinessThe Journal of Laryngology & Otology
researchProduct

Endonasal Approach for Nasal and Paranasal Sinus Tumor Removal

2001

Patients with benign (53) and malignant (22) tumors of the nose and paranasal sinuses were treated for tumor removal via an endonasal approach. Patient selection was based on tumor location (centrally) rather than histology. Tumors attainable by the endonasal approach were located in the nasal cavity, the ethmoid sinus, the sphenoid sinus and the medial wall of the maxillary sinus. Endonasal microscopic techniques including endonasal orbital decompression and endonasal closure of CSF-leaks were combined with surgical navigation tools in selected cases. Surgical trauma and morbidity could be minimized without compromising radicality of tumor removal. Postoperative hospitalization was compara…

AdultMaleNasal cavitymedicine.medical_specialtyAdolescentMaxillary sinusNose NeoplasmsEthmoid sinusParanasal Sinusesotorhinolaryngologic diseasesmedicineHumansChildSinus (anatomy)NoseAgedRetrospective StudiesAged 80 and overIntraoperative Carebusiness.industryPatient SelectionParanasal Sinus TumorInfantEndoscopyMiddle AgedSurgeryRadiographyTreatment OutcomeParanasal sinusesmedicine.anatomical_structureOtorhinolaryngologyChild PreschoolFemaleTumor removalNeoplasm Recurrence LocalbusinessORL
researchProduct

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma : results From the Open-Label, Multicenter, Phase II DAWN Study

2018

Purpose The Bruton's tyrosine kinase inhibitor ibrutinib has demonstrated clinical activity in B-cell malignancies. The DAWN study assessed the efficacy and safety of single-agent ibrutinib in chemoimmunotherapy relapsed/refractory follicular lymphoma (FL) patients. Methods DAWN was an open-label, single-arm, phase II study of ibrutinib in patients with FL with two or more prior lines of therapy. Patients received ibrutinib 560 mg daily until progressive disease/unacceptable toxicity. The primary objective was independent review committee–assessed overall response rate (ORR; complete response plus partial response). Exploratory analyses of T-cell subsets in peripheral blood (baseline/cycle …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classFollicular lymphomaPhases of clinical researchTyrosine-kinase inhibitor03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePiperidinesRecurrenceT-Lymphocyte SubsetsChemoimmunotherapyInternal medicineBiomarkers TumormedicineHumansLymphoma FollicularProtein Kinase InhibitorsAgedAged 80 and overManchester Cancer Research Centrebusiness.industryResearchInstitutes_Networks_Beacons/mcrcAdenineMiddle Agedmedicine.diseaseLymphomaPyrimidinesTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisIbrutinibPyrazolesFemaleRefractory Follicular LymphomabusinessProgressive disease030215 immunology
researchProduct

Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity

2006

This study tested the hypothesis that GLUT-1 is a marker of radioresistance in oral squamous cell carcinomas (OSCC). A GLUT-1 labeling index (LI) was determined by immunohistochemistry in 40 pretreatment OSCC biopsies. Radiation responses were categorized by histopathology of the resection specimens. Associations between the LI and radiation response, Kaplan-Meier survival estimates and Cox regression analysis for the variables GLUT-1, T-stage, N-stage and chemotherapy were examined. The median LI was 64.2% (range 14-100%). Tumors with65% of GLUT-1+cells were more resistant to radiation (p=0.023). Overall survival was higher (p=0.044) for subjects with low LI (median value) than those with …

AdultMaleOncologyendocrine systemCancer Researchmedicine.medical_specialtyPathologymedicine.medical_treatmentAntineoplastic AgentsRadiation ToleranceImmunoenzyme TechniquesRadioresistanceInternal medicineBiomarkers TumorHumansMedicineAgedRetrospective StudiesGlucose Transporter Type 1Chemotherapybusiness.industryProportional hazards modelHead and neck cancerMiddle AgedPrognosismedicine.diseaseCombined Modality TherapySurvival AnalysisNeoplasm ProteinsRadiation therapystomatognathic diseasesTreatment OutcomeOncologyEpidermoid carcinomaCarcinoma Squamous CellImmunohistochemistryFemaleMouth NeoplasmsHistopathologyOral Surgerybusinesshormones hormone substitutes and hormone antagonistsOral Oncology
researchProduct

Tumors of the salivary gland in Mexicans. A retrospective study of 360 cases

2011

Objective: To establish distribution frequency and demographic characteristics of salivary gland tumours (SGT) i6n order to identify possible risk profiles. Design of study: The present report constitutes an eight year retrospective study (January 2000-August 2007). The archives of the Clinical and Experimental Pathology Laboratory (Graduate and Research Division, Dental School, National Autonomous University of Mexico) as well as archives of the Surgical Pathology Service (General Hospital, Mexico City) were subject to revision in order to select all cases where SGT tumour diagnoses were emitted. Age and gender of patients as well as SGT topography were obtained from medical records. Selec…

AdultMalePathologymedicine.medical_specialtyAdenoid cystic carcinomaPleomorphic adenomaSurgical pathologyYoung AdultMucoepidermoid carcinomaRisk FactorsMajor Salivary GlandPapillary CystadenomamedicineHumansGeneral DentistryMexicoAgedRetrospective StudiesAged 80 and overOral Medicine and PathologySalivary glandbusiness.industryMiddle Agedmedicine.diseaseSalivary Gland Neoplasms:CIENCIAS MÉDICAS [UNESCO]Parotid glandmedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemalebusiness
researchProduct